Hemovent GMBH
Portable heart-lung machine for bedside use
This article was originally published in Start Up
Executive Summary
Hemovent GMBH has developed a miniaturized extracorporeal membrane oxygenation system for bedside use in intensive care. The start-up says the footprint of its ECMO is just 10% the size of the smallest commercially available heart-lung machine, and the cost of the unit is 95% less than a standard ECMO device.
You may also be interested in...
Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations
US FDA hits firms in New Jersey, South Korea and China with warning letters. Meanwhile, Catalent and several outsourcing facilities work on Form 483 inspection findings as Mylan, Viona and Lohxa announce drug recalls.
US FDA’s New Drug Median Review Time Held Steady At Eight Months In 2021
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).